



Indrayani Biotech Limited

1133/5 F C Road, Opp. Police Grounds

Pune 411 016

Tel/Fax: +91 20 25662021

CIN: L24231PN1992PLC065801

24, Jan 2019

To

The Bombay Stock Exchange
Department of Corporate Service
25th Floor, P J Towers, Dalal Street
Mumbai – 400001

Dear Sir:

Ref: Scip code "526445"

Sub: Outcome of the Board meeting held on 24.01.2019- Unaudited Financial Results for the quarter ended 31 12 2018.

The Board at its meeting held on 24.01.2019 considered and approved the unaudited financial results of the company for the quarter ended 31 12 2018.

1. Pursuant to clause 33 of the LODR, we enclose the following :

- a) statement of unaudited Financial Results for the quarter ended 31 12 2018.
- b) The Limited Review Report on the said financials for the quarter ended 31 12 2018.

2. The Board considered and approved the amalgamation of the Company with 1) Helios Solutions Ltd and 2) A-Diet Express Hospitality Service Ltd with the Company w.e.f. 01.04.2018 (appointed date) subject to various approvals and sanctions to be obtained. Pursuant to SEBI's circular : CFD/Dir3/CIR/2017 21/MAR, 10TH 2017 the Board will submit the draft documents for the said amalgamation as required under clause 37 of LODR and adopt the same in the next Board meeting. The scheme of said amalgamation will be hosted on the website of the Company upon submission of the documents with BSE.

The Board meeting commenced at 3 pm and concluded at 6.15 pm.

Please notify the above to the members of the stock exchange.

Thanking you,

Yours faithfully,

For **INDRAYANI BIOTECH LTD**

Managing Director, **Managing Director**



INDRAYANI BIOTECH LIMITED

Regd. Office: 1133/5, F. C. Road, Opp. Police Grounds, Pune - 411 016.

Telefax: 020 - 25662021, Web: www.indrayani.com, Email: info@indrayani.com, CIN: L40100PN1992PLC065801

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2018

PARTICULARS	Quarter Ended						Rs. In Lakhs	
	31 st December, 2018		30 th September, 2018		30 th September, 2017		Year Ended	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income								
I Revenue from Operations	-	-	-	-	-	-	-	-
II Other Income	-	-	-	-	-	-	-	-
III Total Income	-	-	-	-	-	-	-	-
IV Expenses								
Cost of Materials consumed	-	-	-	-	-	-	-	-
Purchase of stock-in-trade	-	-	-	-	-	-	-	-
Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-	-	-
Employee benefits expenses	-	-	-	-	-	-	-	-
Finance Cost	0.60	0.90	0.90	0.90	0.90	2.10	2.40	3.60
Depreciation and amortisation expense	-	-	-	-	-	0.02	0.02	0.02
Other expenses								
1. Advertisements	0.33	0.13	0.54	0.15	0.15	1.10	0.47	0.71
2. Audit Fees	-	-	-	-	-	-	-	0.71
3. Legal & Professional Expenses	0.61	0.05	3.48	0.94	0.94	4.47	4.48	6.89
4. Rates & Taxes	-	-	-	-	-	0.03	0.03	0.03
5. Telephone & Postage & Courier	0.01	0.01	-	-	-	0.01	0.01	0.01
6. Travelling & Conveyance	-	-	-	-	-	-	-	0.05
7. Filing Fees & Subscription	0.12	0.03	0.12	0.22	0.22	0.46	0.31	0.39
8. Printing & Stationery	0.50	0.12	-	-	-	0.51	0.12	-
9. Prior Period Expenses	-	-	-	-	-	-	-	-
10. Business Promotion	-	-	0.02	-	-	0.02	-	-
Total Other Expenses	1.58	0.34	4.17	1.31	1.31	6.60	5.42	8.78
Total Expenses (IV)	2.18	1.24	5.07	2.21	2.21	8.70	7.84	12.40
Profit / (Loss) before exceptional and tax (I-IV)	(2.18)	(1.24)	(5.07)	(2.21)	(2.21)	(8.70)	(7.84)	(12.40)
VI Exceptional Items	-	-	-	-	-	-	-	-



Handwritten signature/initials

INDRAYANI BIOTECH LIMITED

Regd. Office: 1133/5, F. C. Road, Opp. Police Grounds, Pune - 411 016.
 Web: www.indrayani.com, Email: info@indrayani.com, CIN: L40100PN1992PLC065801
 Telefax: 020 - 25662021

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2018

VII	Profit / (Loss) before tax (V-VI)	(2.18)	(1.24)	(5.07)	(8.70)	(7.84)	(12.40)
VIII	Tax expense						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(2.18)	(1.24)	(5.07)	(8.70)	(7.84)	(12.40)
X	Profit / (Loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	Net Profit / (Loss) from Discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX+XII)	(2.18)	(1.24)	(5.07)	(8.70)	(7.84)	(12.40)
XIV	Other Comprehensive Income (OCI)						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period).						
XVI	Earnings per share (for continuing operation)						
	Basic:	(0.06)	(0.03)	(0.14)	(0.24)	(0.22)	(0.34)
	Diluted:	(0.06)	(0.03)	(0.14)	(0.24)	(0.22)	(0.34)
XVII	Earnings per share (for discontinued operation):						
	Basic:						
	Diluted:						
XVIII	Earnings per share (for discontinued & continuing operation)						
	Basic:	(0.06)	(0.03)	(0.14)	(0.24)	(0.22)	(0.34)
	Diluted:	(0.06)	(0.03)	(0.14)	(0.24)	(0.22)	(0.34)



K. J. Jangir

INDRAYANI BIOTECH LIMITED

Regd. Office: 1133/5, F. C. Road, Opp. Police Grounds, Pune - 411 016.

Telefax: 020 - 25662021, Web: www.indrayani.com, Email: info@indrayani.com, CIN: L40100PN1992PLC065801

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2018

Notes:

1. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 24th January, 2019. The above financial results are subject to "Limited Review" by the Statutory Auditors of the Company.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies to the extent applicable.
3. The format for unaudited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated 30th November 2015 has been modified to comply with the requirements of SEBI's circular dated 05th July 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013, which are applicable to companies that are required to comply with Ind AS.
4. The Company operates in a single business segment. Hence, no segment wise results are given.
5. The standalone financial results are being forwarded to the Bombay Stock Exchange (BSE) and are also available on the Company website (www.indrayani.com).
6. The Board of Directors of Indrayani Biotech Limited at its meeting on 24th January, 2019 has approved the scheme of arrangement inter-alia provides for merger of Helios Solutions Limited, A-Diet Express Hospitality Services Limited with the Company.

For Indrayani Biotech Limited
For INDRAYANI BIOTECH LTD



Managing Director
Sayee Sundar Kasiraman
Managing Director
DIN: 01295584



Date: 24th January, 2019
Place: Chennai



Limited Review Report on Quarterly Standalone Financial Results of INDRAYANI BIOTECH LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors,

INDRAYANI BIOTECH LIMITED

We have reviewed the accompanying statement of unaudited standalone financial results of **INDRAYANI BIOTECH LIMITED** ('the Company') for the quarter ended December, 31st, 2018 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (Listing Regulations).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 24th January, 2019. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagement to Review financial statements', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, Nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for Venkatesh and Co,
Chartered Accountants
Fr.No 004636S


CA Dasaraty V
M.No 026336
Partner



Place: Chennai
Date: 24/01/2019